Xiudong Guan

Xiudong Guan

Auto-generated profile, based on publicly available information

Xiudong Guan

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XGXiudong Guan
Xiudong Guan
LLLanxin Luo
Lanxin Luo
GBGulnaz Begum
Gulnaz Begum
Gary KohanbashGary Kohanbash
Gary Kohanbash
QSQing-Kun Song
Qing-Kun Song
WJWang Jia
Wang Jia
Sodium/hydrogen exchanger 1 (NHE1), encoded by the SLC9A1 gene (SoLute Carrier family 9A1) in humans, is the main H+ efflux mechanism in maintaining alkaline intracellular pH (pHi) and Warburg effects in glioma. However, to date, there are no clinical studies exploring pharmacological inhibition of NHE1 protein in cancer treatment. In this study, we investigated NHE1 expression in gliomas and its relationship with glioma clinical outcome. The Chinese Glioma Genome Atlas (CGGA) dataset containing transcriptome sequencing data of 325 glioma samples and the Cancer Genome Atlas (TCGA) with 698 glioma mRNAseq data were analyzed in this study. Mouse SB28 and GL26 intracranial syngeneic glioma models in C57BL/6 J mice were established to investigate NHE1 expression and impact of NHE1 protein inhibition with its inhibitor HOE642 on tumorigenesis and anti-PD1 therapy. Tumor angiogenesis, immunogenicity, and progression were assessed by immunofluorescence staining and flow cytometric profiling. Analysis of SLC9A1 mRNA expression in two data sets, CGGA and TCGA, reveals significantly higher SLC9A1 mRNA levels in higher grade gliomas. The SLC9A1 mRNA expression was especially enriched in isocitrate dehydrogenase (IDH)1/2 wild-type glioblastoma (GBM) and in mesenchymal glioma subtypes. Worsened survival probabilities were correlated with the elevated SLC9A1 mRNA levels in gliomas. The underlying mechanisms include promoting angiogenesis, and extracellular matrix remodeling. Increased SLC9A1 mRNA expression was also associated with tumor-associated macrophage accumulation. NHE1 inhibitor HOE642 reduced glioma volume, invasion, and prolonged overall survival in mouse glioma models. Blockade of NHE1 protein also stimulated immunogenic tumor microenvironment via activating CD8 T-cell accumulation, increasing expression of interferon-gamma (Ifng), and sensitized animals to anti-PD-1 therapy. Our findings strongly suggest that NHE1 protein emerges as a marker for tumorigenesis and prognosis in glioma. Blocking NHE1 protein is a novel strategy for adjuvant anti-cancer therapies.

31 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YWYangyang Wang
Yangyang Wang
YLYan Liu
Yan Liu
CZChengkai Zhang
Chengkai Zhang
CZChuanbao Zhang
Chuanbao Zhang
XGXiudong Guan
Xiudong Guan
WJWang Jia
Wang Jia
Background: Macrophages, the major immune cells in glioma microenvironment, are closely related to tumor prognosis. Further studies are needed to investigate macrophages, which will be helpful to fully understand the role of it and early achieve clinical translation.Methods: A total of 1334 glioma cases were enrolled in this study from 3 databases. In our works, the single cell cohorts from GSE89567, GSE84465, and the Chinese Glioma Genome Atlas (CGGA) datasets were used to analyze the key genes of macrophage. The bulk sequencing data from the Cancer Genome Atlas (TCGA) and CGGA datasets were respectively divided into the training set and validation set to test prognostic value of the key genes from single cell analysis.Results: Quantitative and functional differences significantly emerge in macrophage clusters between LGG and GBM. Firstly, we used the Seurat R package to identify 281 genes differentially expressed genes in macrophage clusters between LGG and GBM. Furthermore, based on these genes, we developed a predictive risk model to predict prognosis and reflect the immune microenvironment in glioma. The risk score calculation formula was yielded as follows: Risk score = (0.11 × EXPMACC1) + (−0.31 × EXPOTUD1) + (−0.09 × EXPTCHH) + (0.26 × EXPADPRH) + (-0.40× EXPABCG2) + (0.21 × EXPPLBD1) + (0.12 × EXPANG) + (0.29 × EXPQPCT). The risk score was independently related to prognosis. Further, significant differences existed in immunological characteristics between the low- and high-risk score groups. What is more, mutation analysis found different genomic patterns associated with the risk score.Conclusion: This study further confirms that the proportion of macrophage infiltration is not only significantly different, but the function of them is also different. The signature, identified from the differentially expressed macrophage-related genes impacts poor prognosis and short overall survival and may act as therapeutic targets in the future.

24 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
CZChengkai Zhang
Chengkai Zhang
SMShunchang Ma
Shunchang Ma
DXDan Xiao
Dan Xiao
LZLuwen Zhang
Luwen Zhang
SGSongbai Gui
Songbai Gui
WJWang Jia
Wang Jia
Background: The comparative efficacy of endoscopic versus microscopic transsphenoidal surgery for patients with pituitary adenoma (PA) remains controversial. Previous retrospective studies have often been limited by inconsistencies in baseline characteristics of patients, which may affect the validity of the comparisons. This study aimed to evaluate the trend in the proportion of transsphenoidal endoscopic and microscopic surgeries in China and compare outcomes in comparable patients. Materials and methods: The National Brain Tumor Registry of China (NBTRC) database was queried to extract PA patients (2011–2021) for trend analysis. Stratified sampling was performed, and a 1:1 propensity score matching (PSM) was used to balance the patients’ baseline characteristics. Postoperative outcomes, complications, and prognosis were compared. Results: Among the nationwide 17 012 PA patients, there was a gradual increase in the proportion of endoscopic surgeries (annual percent change, 11.89%). Among the 1863 stratified patients, those who underwent endoscopic surgery had a higher preoperative recurrence rate and higher Knosp and Hardy grades ( P < 0.05). Endoscopic surgery showed a similar gross total resection (GTR) rate to microscopy (55.6% vs. 54.9%, P = 0.886) in the real-world cohort and a higher GTR rate (59.5% vs. 54.3%, P = 0.037) in the PSM cohort. After PSM, there was no significant difference in cerebrospinal fluid leak and secondary surgery ( P > 0.05); endoscopic surgery showed more bleeding, longer surgical time, shorter hospital stay, and higher costs (all P < 0.001) compared to microscopic surgery. The risk of postoperative progression was similar between endoscopic and microscopic surgeries for comparable PA patients ( P = 0.45). Conclusion: Endoscopic transsphenoidal surgery is increasingly adopted in China, demonstrating a higher GTR rate than microscopic transsphenoidal surgery in PA patients with similar characteristics, without increasing severe complication rates. The risk of postoperative progression was similar between the two techniques.

25 August 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YWYangyang Wang
Yangyang Wang
LMLi Ma
Li Ma
CZChuanbao Zhang
Chuanbao Zhang
SMShunchang Ma
Shunchang Ma
GJGuijun Jia
Guijun Jia
XGXiudong Guan
Xiudong Guan
Background: Growth hormone‐secreting pituitary neuroendocrine tumors (GH‐secreting PitNETs) pose significant health risks due to hormone‐related complications. Despite transsphenoidal surgical resection being the primary treatment, complete removal is often infeasible due to invasive growth patterns, leading to postoperative tumor residuals and uncertain hormone remission outcomes.Methods: This retrospective study included 458 patients with GH‐secreting PitNETs who underwent surgery at Beijing Tiantan Hospital. Data on preoperative hormone levels, MRI scans, and histopathological features were analyzed. Tumor segmentation, intratumor heterogeneity (ITH) scores, and subcluster clustering based on MRI data were computed using radiomic features, while multivariate analyses determined factors influencing hormone remission. Single‐cell data from four GH‐type pituitary adenomas were collected from public databases to explore ITH in GH1 gene expression.Results: Postoperative hormone remission was achieved in 61 of 144 patients (42.4%) with residual tumors. Univariate analysis demonstrated that in cases with tumor residuals, preoperative hormone levels, tumor resection rates, residual tumor volume, tumor residual location, residual‐tumor proximity to the internal carotid artery, and MRI‐based tumor heterogeneity were associated with hormone remission. Among these factors, preoperative hormone levels (10–30 ng/mL vs. ≤ 10 ng/mL: OR: 0.48, 95% CI 0.20–1.19, p = 0.115; > 30 ng/mL vs. ≤ 10 ng/mL: OR: 0.13, 95% CI: 0.04–0.36, p < 0.001), tumor resection rate (OR: 18.29, 95% CI: 2.08–160.97, p = 0.009), and tumor heterogeneity as measured by the ITH score (OR: 1.06, 95% CI: 1.00–1.12, p = 0.042) were independent predictors of hormone remission in cases with residual tumors. Moreover, single‐cell data showing highly variable GH1 expression within the same patient reveal ITH in hormone expression.Conclusion: Preoperative GH levels, tumor resection rates, and ITH scores independently predict hormone remission in GH‐secreting PitNETs with residuals. This will provide intraoperative decision‐making guidance on how to achieve the maximum possible hormone remission with residual tumors when complete tumor resection is not feasible.

1 January 2023 in Open Medicine
Verified
Journal Article
Open access
PDF file
CZChengkai Zhang
Chengkai Zhang
WZWenjianlong Zhou
Wenjianlong Zhou
DZDainan Zhang
Dainan Zhang
SMShunchang Ma
Shunchang Ma
XWXi Wang
Xi Wang
KQKe Qian
Ke Qian
More clinical evidence is needed regarding the relative priority of treatments for brain metastases (BMs) from EGFR/ALK-negative/unselected non-small cell lung cancer (NSCLC). PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov databases were searched. Overall survival (OS), central nervous system progression-free survival (CNS-PFS), and objective response rate (ORR) were selected for Bayesian network meta-analyses. We included 25 eligible randomized control trials (RCTs) involving 3,054 patients, investigating nine kinds of treatments for newly diagnosed BMs and seven kinds of treatments for previously treated BMs. For newly diagnosed BMs, adding chemotherapy, EGFR-TKIs, and other innovative systemic agents (temozolomide, nitroglycerin, endostar, enzastaurin, and veliparib) to radiotherapy did not significantly prolong OS than radiotherapy alone; whereas radiotherapy + nitroglycerin showed significantly better CNS-PFS and ORR. Surgery could significantly prolong OS (hazard ratios [HR]: 0.52, 95% credible intervals: 0.41–0.67) and CNS-PFS (HR: 0.32, 95% confidence interval: 0.18–0.59) compared with radiotherapy alone. For previously treated BMs, pembrolizumab + chemotherapy, nivolumab + ipilimumab, and cemiplimab significantly prolonged OS than chemotherapy alone. Pembrolizumab + chemotherapy also showed better CNS-PFS and ORR than chemotherapy. In summary, immune checkpoint inhibitor (ICI)-based therapies, especially ICI-combined therapies, showed promising efficacies for previously treated BMs from EGFR/ALK-negative/unselected NSCLC. The value of surgery should also be emphasized. The result should be further confirmed by RCTs.

2 February 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
YLYuqi Liu
Yuqi Liu
CSChen Sun
Chen Sun
YNYuning Niu
Yuning Niu
XWXu Wang
Xu Wang
ZYZehua Yue
Zehua Yue
WJWang Jia
Wang Jia
Brain tumor MRI segmentation and classification are essential for preoperative boundary assessment, lesion burden quantification, postoperative response monitoring, and radiotherapy planning, yet edema overlap, sequence heterogeneity, and artifacts often blur lesion margins. Together with the high cost of pixel-level annotation, these factors limit robust, cross-institution deployment. We propose DARE-FUSE (Domain Aligned Representation with Evidence-guided FUSE), a unified framework for pixel-level segmentation and image-level classification under limited samples and labels. Dual encoders with a feature-interaction bridge learn a shared embedding, and a Domain Alignment Refiner maps it to task-aligned representations for the segmentation and classification branches. For segmentation, U-SEG decodes features and SEGU outputs pixel-wise uncertainty to regularize boundary over/under-segmentation. For classification, CPG produces predictions and multi-scale Grad-CAM++ evidence. A Generative Lesion Removal Prior reconstructs a tumor-free counterpart to yield a difference prior, and FUSE combines this prior with Grad-CAM++ under uncertainty attenuation to guide segmentation and suppress hallucinations. DARE-FUSE achieves stable, leading performance on BraTS segmentation benchmarks and several classification datasets; ablations and label-reduction experiments confirm complementary gains and smooth degradation as pixel annotations decrease. The resulting uncertainty maps and continuous priors support interpretable decision assistance in surgery, radiotherapy contouring, triage, and longitudinal follow-up.